Potential predictive markers of response to EGFR-targeted therapies in colorectal cancer.

摘要: The importance of the epidermal growth factor receptor (EGFR) axis in tumorigenesis and tumor progression makes it an attractive target for development anticancer therapies. Strategies aimed at inhibiting EGFR pathway included different classes compounds, with monoclonal antibodies tyrosine kinase inhibitors being most widely-investigated agents colorectal cancer. Although anti-EGFR therapies are active some patients, disease will become refractory to therapy nearly all patients. Identification specific markers likely predict which patients best respond is a major challenge. While occurrence rash associated greater likelihood response, staining by immunohistochemistry baseline not. Among biological predictors, studies indicate that activated EGFR, amplification, absence KRAS mutations, PTEN expression, low VEGFR expression implicated response antibodies. Moreover, germinal gene polymorphisms, such as dinucleotide repeats polymorphism or FcgammaR polymorphism, have been shown be therapy. Since available data come from retrospective studies, there need validate these results prospective trials.